Teva Pharmaceuticals USA Inc recalls IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only, Teva Pharmac
Recalled April 20, 2022 · FDA recall D-0765-2022 · Teva Pharmaceuticals USA
Hazard
Presence of Particulate Matter: Product was found to contain silica and iron oxide · FDA Class I
Units
1565 vials
Sold at
Nationwide within the United States
Description
Presence of Particulate Matter: Product was found to contain silica and iron oxide
Product
IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only, Teva Pharmaceuticals, USA, Inc., North Wales, PA 19454, NDC 0703-4154-11.
Manufacturer(s)
Teva Pharmaceuticals USA Inc
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →